

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Finasteride (1%) Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
Shotton Lane  
NE23 3JU Cramlington NU - Great Britain

Telephone : +44 1 670 59 32 05

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

**Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

Reproductive toxicity, Category 1B  
Specific target organ toxicity - repeated exposure, Category 2  
Long-term (chronic) aquatic hazard, Category 3

H360D: May damage the unborn child.  
H373: May cause damage to organs through prolonged or repeated exposure.  
H412: Harmful to aquatic life with long lasting effects.

#### 2.2 Label elements

**Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H360D      May damage the unborn child. H373      May cause damage to organs through prolonged or repeated exposure. H412      Harmful to aquatic life with long lasting effects.
Precautionary statements	:	<b>Prevention:</b> P201      Obtain special instructions before use. P260      Do not breathe dust. P273      Avoid release to the environment. P280      Wear protective gloves/ protective clothing/ eye protection/ face protection. <b>Response:</b> P308 + P313      IF exposed or concerned: Get medical advice/ attention. <b>Storage:</b> P405      Store locked up.

Hazardous components which must be listed on the label:  
Finasteride

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.  
Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Finasteride	98319-26-7	Acute Tox. 4; H302 Repr. 1B; H360D STOT RE 1; H372 (Testis) Aquatic Chronic 1; H410	>= 1 - < 2.5

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

		M-Factor (Chronic aquatic toxicity): 1	
Substances with a workplace exposure limit :			
Cellulose	9004-34-6 232-674-9		>= 1 - < 10
Starch	9005-25-8 232-679-6		>= 1 - < 10

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Metal oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

---

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

dust of any kind      10 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (Inhalable)  
Basis: GB EH40

4 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (Respirable fraction)  
Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m <sup>3</sup>	GB EH40
		TWA (Respirable dust)	4 mg/m <sup>3</sup>	GB EH40
		STEL (inhalable dust)	20 mg/m <sup>3</sup>	GB EH40
Starch	9005-25-8	TWA (inhalable dust)	10 mg/m <sup>3</sup>	GB EH40
		TWA (Respirable dust)	4 mg/m <sup>3</sup>	GB EH40
Finasteride	98319-26-7	TWA	0.5 µg/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	5 µg/100 cm <sup>2</sup>	Internal

### 8.2 Exposure controls

#### Engineering measures

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Appearance	:	powder
Colour	:	tan
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper	:	No data available

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

flammability limit

Lower explosion limit / Lower  
flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-  
octanol/water : log Pow: 3.5  
pH: 7  
Active ingredient

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

### 9.2 Other information

Flammability (liquids) : No data available

Particle size : No data available

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

#### Components:

##### **Finasteride:**

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg  
LD50 (Mouse): 486 mg/kg

##### **Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

##### **Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

#### **Skin corrosion/irritation**

Not classified based on available information.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

---

### Components:

#### **Finasteride:**

Species : Rabbit  
Result : No skin irritation

#### **Serious eye damage/eye irritation**

Not classified based on available information.

### Components:

#### **Finasteride:**

Species : Rabbit  
Remarks : slight irritation

#### **Starch:**

Species : Rabbit  
Result : No eye irritation

#### **Respiratory or skin sensitisation**

##### **Skin sensitisation**

Not classified based on available information.

##### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Starch:**

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Finasteride:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

---

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Application Route: Oral  
Result: negative

### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

### Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Finasteride:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
: 160 mg/kg body weight  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

Species : Mouse  
Application Route : Ingestion  
Exposure time : 19 month(s)  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

### Reproductive toxicity

May damage the unborn child.

### Components:

#### Finasteride:

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 80 mg/kg body weight  
Result: No effects on fertility
- Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: LOAEL: 80 mg/kg body weight  
Result: positive  
Remarks: There is no evidence that these findings are relevant to humans.
- Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 0.003 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects.
- Test Type: Embryo-foetal development  
Species: Monkey  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Teratogenic effects
- Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

#### Cellulose:

- Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative
- Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version 4.2      Revision Date: 06.04.2024      SDS Number: 9371529-00007      Date of last issue: 30.09.2023  
Date of first issue: 27.08.2021

---

### Components:

#### **Finasteride:**

Exposure routes : Ingestion  
Target Organs : Testis  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

#### Components:

#### **Finasteride:**

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

Species : Dog  
NOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

#### **Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

#### **Starch:**

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

### **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

#### Components:

#### **Finasteride:**

Ingestion : Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Finasteride:**

- |  |   |  |
|--|---|--|
| Toxicity to fish   | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 20.4 mg/l<br>Exposure time: 96 h<br>Method: FDA 4.11                 |
| Toxicity to daphnia and other aquatic invertebrates                    | : | EC50 (Daphnia magna (Water flea)): 17.8 mg/l<br>Exposure time: 48 h<br>Method: FDA 4.08                          |
| Toxicity to algae/aquatic plants                                       | : | NOEC (Pseudokirchneriella subcapitata (green algae)): 49 mg/l<br>Exposure time: 14 h<br>Method: FDA 4.01         |
| Toxicity to fish (Chronic toxicity)                                    | : | NOEC: 0.05 mg/l<br>Exposure time: 105 d<br>Species: Oryzias latipes (Orange-red killifish)                       |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC: 0.12 mg/l<br>Exposure time: 21 d<br>Species: Daphnia magna (Water flea)<br>Method: OECD Test Guideline 211 |
| M-Factor (Chronic aquatic toxicity)                                    | : | 1  |

##### **Cellulose:**

- |                  |   |  |
|------------------|---|--|
| Toxicity to fish | : | LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l<br>Exposure time: 48 h<br>Remarks: Based on data from similar materials |
|------------------|---|--|

#### 12.2 Persistence and degradability

##### Components:

##### **Finasteride:**

- |                    |   |   |
|--------------------|---|---|
| Biodegradability   | : | Result: Not readily biodegradable.<br>Biodegradation: 0 %<br>Exposure time: 7 d<br>Method: FDA 3.11 |
| Stability in water | : | Hydrolysis: 0 % (5 d)<br>Method: FDA 3.09   |

##### **Cellulose:**

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

Biodegradability : Result: Readily biodegradable.

### 12.3 Bioaccumulative potential

#### Components:

##### **Finasteride:**

Partition coefficient: n-octanol/water : log Pow: 3.57

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

#### Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

### 14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17) : Not applicable

UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation : Not applicable

The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain) : Not applicable



# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (COMAH)	:	Not applicable

### Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

### Full text of H-Statements

H302	:	Harmful if swallowed.
H360D	:	May damage the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure if swallowed.
H410	:	Very toxic to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
GB EH40	:	UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	:	Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL	:	Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Test-

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



ORGANON

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

ing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 1B	H360D
STOT RE 2	H373
Aquatic Chronic 3	H412

### Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by  
UK REACH Regulations SI 2019/758



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	06.04.2024	9371529-00007	Date of first issue: 27.08.2021

---

GB / EN